Cargando…
Immunotherapeutic Targeting of Membrane Hsp70-Expressing Tumors Using Recombinant Human Granzyme B
BACKGROUND: We have previously reported that human recombinant granzyme B (grB) mediates apoptosis in membrane heat shock protein 70 (Hsp70)-positive tumor cells in a perforin-independent manner. METHODOLOGY/PRINCIPAL FINDINGS: Optical imaging of uptake kinetics revealed co-localization of grB with...
Autores principales: | , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Public Library of Science
2012
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3400620/ https://www.ncbi.nlm.nih.gov/pubmed/22829941 http://dx.doi.org/10.1371/journal.pone.0041341 |
_version_ | 1782238512880287744 |
---|---|
author | Gehrmann, Mathias Stangl, Stefan Kirschner, Andreas Foulds, Gemma A. Sievert, Wolfgang Doß, Brigitte T. Walch, Axel Pockley, Alan G. Multhoff, Gabriele |
author_facet | Gehrmann, Mathias Stangl, Stefan Kirschner, Andreas Foulds, Gemma A. Sievert, Wolfgang Doß, Brigitte T. Walch, Axel Pockley, Alan G. Multhoff, Gabriele |
author_sort | Gehrmann, Mathias |
collection | PubMed |
description | BACKGROUND: We have previously reported that human recombinant granzyme B (grB) mediates apoptosis in membrane heat shock protein 70 (Hsp70)-positive tumor cells in a perforin-independent manner. METHODOLOGY/PRINCIPAL FINDINGS: Optical imaging of uptake kinetics revealed co-localization of grB with recycling endosomes (Rab9/11) as early as 5 min after internalization, with late endosomes (Rab7) after 30 min, and the lysosomal compartment (LAMP1/2) after 60 to 120 min. Active caspase-3-mediated apoptosis was induced in mouse CT26 monolayer cells and 3D tumor spheroids, but not in normal mouse endothelial cells. Granzyme B selectively reduced the proportion of membrane Hsp70-positive cells in CT26 tumor spheroids. Consecutive i.v. injections of recombinant human grB into mice bearing membrane Hsp70-positive CT26 tumors resulted in significant tumor suppression, and a detailed inspection of normal mouse organs revealed that the administration of anti-tumoral concentrations of grB elicited no clinicopathological changes. CONCLUSIONS/SIGNIFICANCE: These findings support the future clinical evaluation of human grB as a potential adjuvant therapeutic agent, especially for treating immunosuppressed patients that bear membrane Hsp70-positive tumors. |
format | Online Article Text |
id | pubmed-3400620 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2012 |
publisher | Public Library of Science |
record_format | MEDLINE/PubMed |
spelling | pubmed-34006202012-07-24 Immunotherapeutic Targeting of Membrane Hsp70-Expressing Tumors Using Recombinant Human Granzyme B Gehrmann, Mathias Stangl, Stefan Kirschner, Andreas Foulds, Gemma A. Sievert, Wolfgang Doß, Brigitte T. Walch, Axel Pockley, Alan G. Multhoff, Gabriele PLoS One Research Article BACKGROUND: We have previously reported that human recombinant granzyme B (grB) mediates apoptosis in membrane heat shock protein 70 (Hsp70)-positive tumor cells in a perforin-independent manner. METHODOLOGY/PRINCIPAL FINDINGS: Optical imaging of uptake kinetics revealed co-localization of grB with recycling endosomes (Rab9/11) as early as 5 min after internalization, with late endosomes (Rab7) after 30 min, and the lysosomal compartment (LAMP1/2) after 60 to 120 min. Active caspase-3-mediated apoptosis was induced in mouse CT26 monolayer cells and 3D tumor spheroids, but not in normal mouse endothelial cells. Granzyme B selectively reduced the proportion of membrane Hsp70-positive cells in CT26 tumor spheroids. Consecutive i.v. injections of recombinant human grB into mice bearing membrane Hsp70-positive CT26 tumors resulted in significant tumor suppression, and a detailed inspection of normal mouse organs revealed that the administration of anti-tumoral concentrations of grB elicited no clinicopathological changes. CONCLUSIONS/SIGNIFICANCE: These findings support the future clinical evaluation of human grB as a potential adjuvant therapeutic agent, especially for treating immunosuppressed patients that bear membrane Hsp70-positive tumors. Public Library of Science 2012-07-19 /pmc/articles/PMC3400620/ /pubmed/22829941 http://dx.doi.org/10.1371/journal.pone.0041341 Text en Gehrmann et al. http://creativecommons.org/licenses/by/4.0/ This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are properly credited. |
spellingShingle | Research Article Gehrmann, Mathias Stangl, Stefan Kirschner, Andreas Foulds, Gemma A. Sievert, Wolfgang Doß, Brigitte T. Walch, Axel Pockley, Alan G. Multhoff, Gabriele Immunotherapeutic Targeting of Membrane Hsp70-Expressing Tumors Using Recombinant Human Granzyme B |
title | Immunotherapeutic Targeting of Membrane Hsp70-Expressing Tumors Using Recombinant Human Granzyme B |
title_full | Immunotherapeutic Targeting of Membrane Hsp70-Expressing Tumors Using Recombinant Human Granzyme B |
title_fullStr | Immunotherapeutic Targeting of Membrane Hsp70-Expressing Tumors Using Recombinant Human Granzyme B |
title_full_unstemmed | Immunotherapeutic Targeting of Membrane Hsp70-Expressing Tumors Using Recombinant Human Granzyme B |
title_short | Immunotherapeutic Targeting of Membrane Hsp70-Expressing Tumors Using Recombinant Human Granzyme B |
title_sort | immunotherapeutic targeting of membrane hsp70-expressing tumors using recombinant human granzyme b |
topic | Research Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3400620/ https://www.ncbi.nlm.nih.gov/pubmed/22829941 http://dx.doi.org/10.1371/journal.pone.0041341 |
work_keys_str_mv | AT gehrmannmathias immunotherapeutictargetingofmembranehsp70expressingtumorsusingrecombinanthumangranzymeb AT stanglstefan immunotherapeutictargetingofmembranehsp70expressingtumorsusingrecombinanthumangranzymeb AT kirschnerandreas immunotherapeutictargetingofmembranehsp70expressingtumorsusingrecombinanthumangranzymeb AT fouldsgemmaa immunotherapeutictargetingofmembranehsp70expressingtumorsusingrecombinanthumangranzymeb AT sievertwolfgang immunotherapeutictargetingofmembranehsp70expressingtumorsusingrecombinanthumangranzymeb AT doßbrigittet immunotherapeutictargetingofmembranehsp70expressingtumorsusingrecombinanthumangranzymeb AT walchaxel immunotherapeutictargetingofmembranehsp70expressingtumorsusingrecombinanthumangranzymeb AT pockleyalang immunotherapeutictargetingofmembranehsp70expressingtumorsusingrecombinanthumangranzymeb AT multhoffgabriele immunotherapeutictargetingofmembranehsp70expressingtumorsusingrecombinanthumangranzymeb |